BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sauerbier A, Aris A, Lim EW, Bhattacharya K, Ray Chaudhuri K. Impact of ethnicity on the natural history of Parkinson disease. Medical Journal of Australia 2018;208:410-4. [DOI: 10.5694/mja17.01074] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Jagtap S, Potdar C, Yadav R, Pal PK, Datta I. Dopaminergic Neurons Differentiated from LRRK2 I1371V-Induced Pluripotent Stem Cells Display a Lower Yield, α-Synuclein Pathology, and Functional Impairment. ACS Chem Neurosci 2022. [PMID: 36006382 DOI: 10.1021/acschemneuro.2c00297] [Reference Citation Analysis]
2 Lau YH, Podlewska A, Ocloo J, Gupta A, Gonde C, Bloem BR, Chaudhuri KR. Does Ethnicity Influence Recruitment into Clinical Trials of Parkinson's Disease? J Parkinsons Dis 2022;12:975-81. [PMID: 35068418 DOI: 10.3233/JPD-213113] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Jagtap S, Sowmithra, Yadav R, Pal PK, Datta I. Generation of induced pluripotent stem cells (NIMHi004-A, NIMHi005-A and NIMHi006-A) from healthy individuals of Indian ethnicity with no mutation for Parkinson’s disease related genes. Stem Cell Research 2022;60:102716. [DOI: 10.1016/j.scr.2022.102716] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Battista VD, Hey-Hawkins E. Development of Prodrugs for Treatment of Parkinson's Disease: New Inorganic Scaffolds for Blood-Brain Barrier Permeation. J Pharm Sci 2022:S0022-3549(22)00070-3. [PMID: 35182542 DOI: 10.1016/j.xphs.2022.02.005] [Reference Citation Analysis]
5 Behl T, Madaan P, Sehgal A, Singh S, Sharma N, Bhatia S, Al-Harrasi A, Chigurupati S, Alrashdi I, Bungau SG. Elucidating the Neuroprotective Role of PPARs in Parkinson's Disease: A Neoteric and Prospective Target. Int J Mol Sci 2021;22:10161. [PMID: 34576325 DOI: 10.3390/ijms221810161] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
6 Dommershuijsen LJ, Boon AJW, Ikram MK. Probing the Pre-diagnostic Phase of Parkinson's Disease in Population-Based Studies. Front Neurol 2021;12:702502. [PMID: 34276552 DOI: 10.3389/fneur.2021.702502] [Reference Citation Analysis]
7 Cacabelos R, Carrera I, Martínez O, Alejo R, Fernández-Novoa L, Cacabelos P, Corzo L, Rodríguez S, Alcaraz M, Nebril L, Tellado I, Cacabelos N, Pego R, Naidoo V, Carril JC. Atremorine in Parkinson's disease: From dopaminergic neuroprotection to pharmacogenomics. Med Res Rev 2021;41:2841-86. [PMID: 34106485 DOI: 10.1002/med.21838] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
8 Hug K. Bringing Advanced Therapies for Parkinson's Disease to the Clinic: An Analysis of Ethical Issues. J Parkinsons Dis 2021. [PMID: 34092655 DOI: 10.3233/JPD-212639] [Reference Citation Analysis]
9 van Wamelen DJ, Sauerbier A, Leta V, Rodriguez-Blazquez C, Falup-Pecurariu C, Rodriguez-Violante M, Rizos A, Tsuboi Y, Metta V, Bhidayasiri R, Bhattacharya K, Borgohain R, Prashanth LK, Rosales R, Lewis S, Fung V, Behari M, Goyal V, Kishore A, Lloret SP, Martinez-Martin P, Chaudhuri KR. Cross-sectional analysis of the Parkinson's disease Non-motor International Longitudinal Study baseline non-motor characteristics, geographical distribution and impact on quality of life. Sci Rep 2021;11:9611. [PMID: 33953218 DOI: 10.1038/s41598-021-88651-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
10 Dos Santos EUD, da Silva IIFG, Asano AGC, Asano NMJ, De Mascena Diniz Maia M, de Souza PRE. Pharmacogenetic profile and the development of the dyskinesia induced by levodopa-therapy in Parkinson's disease patients: a population-based cohort study. Mol Biol Rep 2020;47:8997-9004. [PMID: 33151475 DOI: 10.1007/s11033-020-05956-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
11 Kaiyrzhanov R, Zharkinbekova N, Shashkin C, Khaibullin T, Kaishibayeva G, Akhmetzhanov V, Sadykova DZ, Seidinova Z, Taskinbayeva A, Karimova A, Rizig M, Houlden H. Parkinson's Disease in Kazakhstan: Clinico-Demographic Description of a Large Cohort. J Parkinsons Dis 2020;10:707-9. [PMID: 32144996 DOI: 10.3233/JPD-191782] [Reference Citation Analysis]
12 Sánchez-Martínez CM, Choreño-Parra JA, Placencia-Álvarez N, Nuñez-Orozco L, Guadarrama-Ortiz P. Frequency and Dynamics of Non-motor Symptoms Presentation in Hispanic Patients With Parkinson Disease. Front Neurol 2019;10:1197. [PMID: 31798522 DOI: 10.3389/fneur.2019.01197] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
13 Gilbert RM, Standaert DG. Bridging the Gaps: More Inclusive Research Needed to Fully Understand Parkinson's Disease. Mov Disord 2020;35:231-4. [DOI: 10.1002/mds.27906] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
14 Angelopoulou E, Bozi M, Simitsi A, Koros C, Antonelou R, Papagiannakis N, Maniati M, Poula D, Stamelou M, Vassilatis DK, Michalopoulos I, Geronikolou S, Scarmeas N, Stefanis L. The relationship between environmental factors and different Parkinson's disease subtypes in Greece: Data analysis of the Hellenic Biobank of Parkinson's disease. Parkinsonism & Related Disorders 2019;67:105-12. [DOI: 10.1016/j.parkreldis.2019.08.013] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
15 Alves M, Caldeira D, Ferro JM, Ferreira JJ. Does Parkinson's disease increase the risk of cardiovascular events? A systematic review and meta-analysis. Eur J Neurol 2020;27:288-96. [PMID: 31454134 DOI: 10.1111/ene.14076] [Cited by in Crossref: 13] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
16 du Toit N, van Coller R, Anderson DG, Carr J, Bardien S. Frequency of the LRRK2 G2019S mutation in South African patients with Parkinson’s disease. Neurogenetics 2019;20:215-8. [DOI: 10.1007/s10048-019-00588-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
17 Dos Santos EUD, Duarte EBC, Miranda LMR, Asano AGC, Asano NMJ, Maia MMD, de Souza PRE. Influence of DRD1 and DRD3 Polymorphisms in the Occurrence of Motor Effects in Patients with Sporadic Parkinson's Disease. Neuromolecular Med 2019;21:295-302. [PMID: 31119645 DOI: 10.1007/s12017-019-08549-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
18 Gilbert RM; American Parkinson’s Disease Association (APDA), Staten Island, NY, USA. American Parkinson Disease Association Explores the Current Research in Diverse Parkinson’s Disease Populations. US Neurology 2019;15:63. [DOI: 10.17925/usn.2019.15.2.63] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]